Related Experiment Video
Updated: Jun 27, 2025
Zebrafish Model of Neuroblastoma Metastasis
Published on: March 14, 2021
DFMO inhibition of neuroblastoma tumorigenesis
Divya Gandra1, David H Mulama2, David M Foureau3
1Department of Pediatrics, Penn State Health Children's Hospital, Hershey, Pennsylvania, USA.
Background:
Most high-risk neuroblastoma patients who relapse succumb to disease despite the existing therapy. We recently reported increased event-free and overall survival in neuroblastoma patients receiving difluoromethylornithine (DFMO) during maintenance therapy. The effect of DFMO on cellular processes associated with neuroblastoma tumorigenesis needs further elucidation. Previous studies have shown cytotoxicity with IC50 values >5-15 mM, these doses are physiologically unattainable in patients, prompting further mechanistic studies at therapeutic doses.
Methods:
We characterized the effect of DFMO on cell viability, cell cycle, apoptosis, neurosphere formation, and protein expression in vitro using five established neuroblastoma cell lines (BE2C, CHLA-90, SHSY5Y, SMS-KCNR, and NGP) at clinically relevant doses of 0, 50, 100, 500, 1000, and 2500 μM. Limiting Dilution studies of tumor formation in murine models were performed. Statistical analysis was done using GraphPad and the level of significance set at p = 0.05.
Results:
There was not a significant loss of cell viability or gain of apoptotic activity in the in vitro assays (p > 0.05). DFMO treatment initiated G1 to S phase cell cycle arrest. There was a dose-dependent decrease in frequency and size of neurospheres and a dose-dependent increase in beta-galactosidase activity in all cell lines. Tumor formation was decreased in xenografts both with DFMO-pretreated cells and in mice treated with DFMO.
Conclusion:
DFMO treatment is cytostatic at physiologically relevant doses and inhibits tumor initiation and progression in mice. This study suggests that DFMO, inhibits neuroblastoma by targeting cellular processes integral to neuroblastoma tumorigenesis at clinically relevant doses.
Insights
Difluoromethylornithine (DFMO) shows promise in treating high-risk neuroblastoma by halting cancer cell cycle progression and reducing tumor formation in mice at therapeutic doses.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- High-risk neuroblastoma patients often experience disease relapse despite current therapies.
- Difluoromethylornithine (DFMO) has shown potential in improving survival rates for neuroblastoma patients.
- Mechanistic studies are needed to understand DFMO's effects at physiologically relevant doses.
Purpose of the Study:
- To elucidate the effects of difluoromethylornithine (DFMO) on neuroblastoma cellular processes at clinically relevant doses.
- To investigate DFMO's impact on cell viability, cell cycle, apoptosis, and neurosphere formation.
- To evaluate DFMO's efficacy in inhibiting tumor initiation and progression in preclinical models.
Main Methods:
- In vitro characterization of DFMO effects on five neuroblastoma cell lines at doses ranging from 0 to 2500 μM.
- Assessment of cell viability, cell cycle progression, apoptosis, and neurosphere formation.
- In vivo studies using murine models to evaluate tumor formation with DFMO treatment.
Main Results:
- DFMO treatment at therapeutic doses did not significantly reduce cell viability or increase apoptosis in vitro.
- DFMO induced a G1 to S phase cell cycle arrest and a dose-dependent decrease in neurosphere formation.
- DFMO significantly inhibited tumor formation in murine xenograft models.
Conclusions:
- Difluoromethylornithine (DFMO) exhibits cytostatic effects at physiologically relevant concentrations.
- DFMO effectively inhibits neuroblastoma initiation and progression by targeting key tumorigenic cellular processes.
- DFMO represents a promising therapeutic agent for high-risk neuroblastoma.
More Related Videos
05:44Author Spotlight: Collecting the Brain and Serum from the Same Mice Fetus to Study Brain Tumor Development
Published on: May 17, 2024
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
